Heron Therapeutics announced the appointment of Brett Fleshman as Chief Business Officer. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. Most recently, Brett Fleshman served as Managing Director at NovaQuest Capital Management.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron reaffirms FY24 revenue view $138.0M-$158.0M, consensus $147.8M
- Heron Therapeutics reports Q2 EPS (6c), consensus (4c)
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
- Is HRTX a Buy, Before Earnings?
- Heron Therapeutics management to meet virtually with Needham
Questions or Comments about the article? Write to editor@tipranks.com